论文部分内容阅读
甾体避孕药被认为是本世纪对人类重大的贡献之一。由于应用者面广量大,用药时间长,而且其制剂种类繁多,配伍不一,因此,它对人体的安全性受到普遍的重视。自从Waine等首次报道口服避孕药Enovid(异炔诺酮配伍炔雌甲醚)可导致服药妇女的糖耐量变化以来,甾体性激素和糖代谢间关系的研究文献,已超过200篇,现将有关资料作一简要综述。一、雌激素 Kalkhoff曾综合报道227例妇女分别口服不同剂量己烯雌酚、Premarin、炔雌甲醚及炔雌醇10天至36个月后,20～33%服药者出现糖耐量下降。己烯雌酚和premarin较炔雌甲醚和炔雌醇为严重。但是,当
Steroid contraceptives are considered one of the major contributions to humankind this century. As a result of a wide range of applications, medication for a long time, but also a wide range of formulations, compatibility, therefore, its safety is generally valued. Since Waine et al. First reported that oral contraceptive Enovid (norethindrone norethindrone plus ethynylestradiol) can lead to changes in glucose tolerance in women taking medication, there have been over 200 articles on the relationship between steroid hormones and glycometabolism. Data for a brief review. Estrogen Kalkhoff has reported a total of 227 cases of women oral administration of different doses of diethylstilbestrol, Premarin, ethinyl estradiol and ethinylestradiol 10 days to 36 months, 20 to 33% of patients with medication decreased impaired glucose tolerance. Diethylstilbestrol and premarin were more severe than ethinyl estradiol and ethinylestradiol. However, when